Fact Check: Did PM Modi promote obesity only after meeting Eli Lilly CEO David Ricks?

Standfirst:
A viral allegation claims Prime Minister Narendra Modi began pushing an obesity narrative only after meeting Eli Lilly CEO David Ricks, and that Indian rules were later changed to help clear the way for Mounjaro. But the documentary record reviewed here shows Modi had publicly linked obesity to public health years earlier, while the regulatory pathway cited in the claim appears to predate the meeting.

A viral claim circulating online alleges that Prime Minister Narendra Modi began publicly emphasizing obesity only after meeting Eli Lilly CEO David Ricks, supposedly as part of a coordinated effort to benefit the company’s weight-loss drug Mounjaro.

The same claim also alleges that Indian drug rules were changed in 2025 to make approval easier for Eli Lilly.

But the documentary material reviewed in the source file does not support either of those central assertions. Instead, it points to a longer public record of Modi discussing obesity, diabetes, fitness and lifestyle disease, and to a regulatory framework that appears to have existed before the meeting cited in the allegation.

The claim

The allegation is built around a video on Narendra Modi’s official YouTube channel in which Eli Lilly CEO David Ricks says he had a “wonderful meeting with PM Modi.” That video is used as a central visual anchor to suggest a political-pharmaceutical link: https://www.youtube.com/watch?v=cr5d5zuuUAU

From there, the allegation advances two factual claims: first, that Modi’s obesity-focused messaging emerged only after that meeting; second, that rules were later changed in 2025 to support Eli Lilly’s approval pathway in India.

The chronology does not hold up

The strongest weakness in the claim is its timeline.

The source material cites a 2015 Mann Ki Baat episode featuring then-US President Barack Obama in which Modi discussed diabetes and obesity: https://www.youtube.com/live/kNBwx1Rvj08?si=llmkCTuBDZ-2w-Eb&t=680

It also includes an archived Indian Express report stating that the person who asked the obesity-related question later claimed the question was “Modi’s idea”

If Modi was publicly discussing obesity in 2015, that substantially undercuts the suggestion that the issue appeared in his messaging only after a much later meeting with Eli Lilly’s CEO.

The record cited in the source continues through 2019. At the launch of the Fit India movement, Modi discussed overeating, dieting, diabetes, hypertension and broader lifestyle disease concerns. The event video is here: https://www.youtube.com/watch?v=Cxfk583i6x4

A Mint report linked in the file also tied the campaign to lifestyle disorders including obesity

According to the research, the speech included remarks on overeating and dieting around 14:12, lifestyle disease around 17:40, and a “fit vs fat” reference around 22:17. That again places the rhetoric years before the alleged trigger point.

There is also a direct official-source reference from August 2022. In the 92nd episode of Mann Ki Baat, published on the PMIndia website, Modi said millets help reduce obesity and lower the risk of diabetes, hypertension and heart disease

That is a clear public reference to obesity from two years before the September 2024 meeting invoked in the allegation.

The regulatory claim is also on shaky ground

The second half of the allegation is that rules were changed in 2025 to make approval easier for Eli Lilly’s drug.

The source material disputes that account, arguing that the relevant waiver logic was already present in India’s New Drugs and Clinical Trials Rules, 2019. Specifically, it points to Rule 75(7), which the file summarizes as allowing local clinical trial requirements to be waived if a drug is already approved and marketed in countries specified by the Central Licensing Authority under Rule 101, subject to conditions.

If that reading is correct, then the central legal pathway cited in the allegation was not newly created in 2025.

The file also points to an approval-related committee document concerning tirzepatide

According to the passage quoted in the source, Eli Lilly told regulators that tirzepatide presentations were already approved in multiple overseas jurisdictions, including the United States, European Union, United Kingdom, United Arab Emirates, Hong Kong, Kuwait, Qatar and Egypt for chronic weight management. The memo argues that this fits an existing approval framework rather than demonstrating a newly invented legal favor.

Rule 101 orders also appear to predate the meeting

The allegation further suggests that the relevant country-waiver setup was part of a later manipulation. But the source file says orders under Rule 101 were already in place before Modi’s meeting with David Ricks.

One example cited is an August 2024 order: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/Orde101%20NDCT.pdf

According to the source, that order covered established regulatory jurisdictions including the US, Japan, the UK and Australia, and predates the meeting timeline used in the allegation. That matters because it suggests the operational mechanism under Rule 101 was active before the event being presented as the turning point.

The bottom line

Taken together, the documents reviewed in the source do not support the claim that Modi’s obesity-related messaging suddenly appeared after meeting Eli Lilly’s CEO. On the contrary, the material points to public references in 2015, 2019 and 2022.

Nor does the source support the claim that the regulatory pathway was specially created in 2025 for Eli Lilly. The record presented here suggests that the relevant waiver structure already existed under the 2019 rules, with Rule 101-linked orders appearing before the meeting cited in the allegation.

That does not resolve every political inference people may want to draw from the meeting or from subsequent approval decisions. But on the narrower factual questions at the center of the viral claim, the available documentary material points away from the allegation, not toward it.